Abstract
The development of PET radiopharmaceuticals for the non-invasive imaging of cancerous lesions, brain receptors, transporters and enzymes started more than 25 years ago. But till today no established algorithms exist to predict the success of a PET radiopharmaceutical. PET radioligand development is a challenging endeavor and predicting the success of PET ligand can be an elusive undertaking. A large number of PET radiopharmaceuticals have been developed for imaging, but so far only a few have found application as imaging agents in vivo in humans. Typically, the potential compound selected for development usually has the desired in vitro characteristics but unknown in vivo properties. The purpose of this chapter is to highlight some of the pharmacological constraints and prerequisites. Interspecies difference in metabolism and mass effects are discussed with examples. Finally, some of the practical issues related to laboratory animal imaging using anesthetic agents are also presented.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ametamey SM, Kessler LJ, Honer M (2006) Radiosynthesis and preclinical evaluation of [11C]-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5 (mGluR5) J Nuc Med 47:698–705
Delaforge M (1998) Importance of metabolism in pharmacological studies: possible in vitro predictability. Nucl Med Biol 25:705–709
Honer M, Hengerer B, Blagoev M et al. (2006) Comparison of 18F-FDOPA, 18F-FMT and 18F-FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol (in press)
Hume SP, Gunn RN, Jones T (1998) Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 25:173–176
Hume SP, Lammertsma AA, Myers R et al. (1996) The potential of high resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J Neurosci Methods 15:103–112
Jagoda EM, Vaquero JJ, Seidel J et al. (2004) Experiment assessment of mass effects in the rat:implications for small animal PET imaging. Nucl Med Biol 31:771–779
Kung MP, Kung HF (2005) Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 32:673–678
Ma Y, Kiesewetter D, Lang L et al. (2003) Application of LC-MS to the analysis of new radiopharmaceuticals. Mol Imaging Biol 5:397–403
Matsumura A, Mizokawa S, Tanaka M et al. (2003) Assessment of microPET performance in analyzing the rat brain under different types of anesthesia: comparison between quantitative data obtained with microPET and ex vivo autoradiography. NeuroImage 20:2040–2050
Momosaki S, Hatano K, Kawasumi Y et al. (2004) Rat-PET study without anesthesia: anesthetics modify the dopamine D1 receptor binding in rat brain. Synapse 54:207–213
Opacka Juffry J, Ahier RG, Cremer JE (1991) Nomifensine-induced increase in extracellular striatal dopamine is enhanced by isoflurane anaesthesia. Synapse 7:169–171
Osman S, Lundkvist C, Pike VW et al. (1996) Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand [O-methyl-11C]-WAY100635 in human and primate plasma by HPLC: Comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl Med Biol 23:627–634
Pike VW, McCarron JA, Hume SP et al. (1995) Preclinical development of a radioligand for studies of central 5-HT1A receptors in vivo-[11C]-WAY100635. Med Chem Res 5:208–227
Shiue CY, Shiue GG, Cornish KG et al. (1995) PET study of the distribution of 11C-fluoxetine in a monkey brain. Nucl Med Biol 22:613–616
Tsukada H, Nishiyama S, Kakiuchi T et al. (1999) Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849:85–96
Votaw J, Byas-Smith M, Hua J et al. (2003) Interaction of isoflurane with the dopamine transporter. Anesthesiology 98:404–411
Wyss MT, Honer M, Schubiger PA et al. (2005) NanoPET imaging of [18F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 33:311–318
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ametamey, S.M., Honer, M. (2007). Pharmacological Prerequisites for PET Ligands and Practical Issues in Preclinical PET Research. In: Schubiger, P.A., Lehmann, L., Friebe, M. (eds) PET Chemistry. Ernst Schering Research Foundation Workshop, vol 64. Springer, Berlin, Heidelberg . https://doi.org/10.1007/978-3-540-49527-7_12
Download citation
DOI: https://doi.org/10.1007/978-3-540-49527-7_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-32623-6
Online ISBN: 978-3-540-49527-7
eBook Packages: MedicineMedicine (R0)